Virax Biolabs Group Limited (VRAX) Key Metrics
VRAX valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $2.0M
- Enterprise value
- −$4.0M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 157.0
- Price / book
- 0.3
- EV / EBITDA
- 0.4
- Dividend yield
- —
- Beta
- 1.39
VRAX key metrics, FY2020–FY2026
Fiscal year ended March 31, 2026 · U.S. dollarsVRAX returns How much profit the business earns on the capital it uses.
VRAX financial health Debt, liquidity and how easily interest is covered.
VRAX efficiency & capital use Working capital cycle and where the cash goes.
VRAX valuation history
VRAX returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
VRAX debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
VRAX price vs earnings per share
VRAX key metrics
FY2020–FY2026| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | |
|---|---|---|---|---|---|---|---|
| Valuation | |||||||
| Market capitalization | $2.2M | — | — | — | — | — | — |
| Enterprise value | −$3.9M | — | — | — | — | — | — |
| Price / sales | 176.0 | — | — | — | — | — | — |
| Price / book | 0.3 | — | — | — | — | — | — |
| EV / sales | -315.3 | — | — | — | — | — | — |
| Earnings yield | −229.7% | — | — | — | — | — | — |
| Free cash flow yield | −223.1% | — | — | — | — | — | — |
| Share price at fiscal year-end | $5.50 | $28.50 | $17.93 | $173.75 | — | — | — |
| Per share | |||||||
| Revenue per share | $0.03 | — | — | — | — | — | — |
| Earnings per share | −$12.64 | — | — | — | — | — | — |
| Operating cash flow per share | −$11.62 | — | — | — | — | — | — |
| Free cash flow per share | −$12.27 | — | — | — | — | — | — |
| Cash per share | $16.39 | — | — | — | — | — | — |
| Book value per share | $19.06 | — | — | — | — | — | — |
| Tangible book value per share | $19.06 | — | — | — | — | — | — |
| Capex per share | $0.64 | — | — | — | — | — | — |
| Debt per share | $1.04 | — | — | — | — | — | — |
| Shares outstanding | 398K | — | — | — | — | — | — |
| Returns & profitability | |||||||
| Return on equity (ROE) | −75.7% | −109.6% | −92.9% | −133.9% | — | — | — |
| Return on invested capital (ROIC) | −304.8% | −253.2% | −534.1% | — | — | — | — |
| Return on assets (ROA) | −68.1% | −101.8% | −88.0% | −110.7% | — | — | — |
| Return on tangible assets | −60.3% | −94.9% | −123.9% | −56.6% | — | −691.7% | — |
| Free cash flow margin | — | — | — | — | — | −476.6% | −745.5% |
| Financial health | |||||||
| Total debt | $414,387 | $377,004 | $224,300 | $146,250 | $3,758 | $179,480 | $759,370 |
| Cash & short-term investments | $6.5M | $4.2M | $3.6M | $9.4M | $21,756 | $17,621 | $22,609 |
| Net debt | −$6.1M | −$3.9M | −$3.4M | −$9.2M | −$17,998 | $161,859 | $736,761 |
| Debt / equity | 0.05 | 0.07 | 0.04 | 0.02 | — | — | — |
| Debt / assets | 0.05 | 0.06 | 0.04 | 0.01 | 0.08 | 1.91 | 33.59 |
| Net debt / EBITDA | — | — | — | — | — | 608.49 | 298.28 |
| Current ratio | 9.97 | 7.27 | 25.94 | 10.61 | 0.04 | 0.05 | 0.02 |
| Quick ratio | 9.90 | 7.13 | 25.58 | 10.58 | 0.02 | 0.02 | 0.02 |
| Interest coverage | -103.6 | -105.9 | -241.7 | -370.6 | -112.3 | -22.5 | -7.2 |
| Working capital | $6.1M | $4.2M | $4.2M | $8.7M | −$1.2M | −$831,814 | −$1.2M |
| Invested capital | $1.5M | $1.8M | $2.0M | −$79,874 | −$992,576 | −$434,326 | −$319,335 |
| Tangible asset value | $7.3M | $5.4M | $5.1M | $8.7M | −$1.2M | −$777,317 | −$1.2M |
| Net current asset value | $5.8M | $3.9M | $4.0M | $8.7M | −$1.2M | −$831,814 | −$1.2M |
| Graham net-net per share | $13.97 | — | — | — | — | — | — |
| Capital allocation | |||||||
| Capex / revenue | 2,059.3% | 9,538.6% | 744.4% | 2,083.9% | — | 0.0% | 0.0% |
| Capex / depreciation | 0.58 | 1.76 | 11.29 | 178,403.00 | 0.00 | 0.00 | 0.00 |
| Stock-based compensation / revenue | 1,049.7% | 5,770.2% | 647.0% | 20,261.7% | — | 0.0% | — |
| R&D / revenue | 30,092.2% | 28,112.5% | 998.6% | 4,638.6% | — | 97.1% | 87.1% |
| SG&A / revenue | 21,484.8% | 68,394.1% | 2,937.5% | 62,309.2% | — | 415.8% | 610.8% |
| Efficiency | |||||||
| Days sales outstanding | — | 7,163.3 | 226.1 | -513.6 | — | 1.4 | 0.0 |
| Days of inventory on hand | 5,503.0 | 476.4 | 145.7 | 828.2 | — | 28.9 | — |
| Days payables outstanding | 4,158.9 | 312.5 | 354.4 | 18,503.4 | — | 588.9 | 1,435.2 |
| Cash conversion cycle (days) | — | 7,327.1 | 17.3 | -18,188.8 | — | -558.7 | -1,435.2 |
| Receivables turnover | — | 0.05 | 1.61 | — | 0.00 | 266.85 | — |
| Payables turnover | 0.09 | 1.17 | 1.03 | 0.02 | 0.00 | 0.62 | 0.25 |
| Inventory turnover | 0.07 | 0.77 | 2.51 | 0.44 | 0.00 | 12.65 | — |
| Asset turnover | 0.00 | 0.00 | 0.02 | 0.00 | 0.00 | 2.12 | 4.42 |
| Average receivables | — | $124,248 | $96,874 | −$12,048 | $464 | $464 | $0 |
| Average payables | $53,930 | $50,862 | $102,770 | $503,191 | $531,810 | $214,990 | $212,835 |
| Average inventory | $71,358 | $77,529 | $42,239 | $22,523 | $21,012 | $10,536 | $0 |
| Intangibles / total assets | 0.0% | 0.6% | 0.9% | 1.8% | 0.0% | 0.0% | 0.0% |
Computed from VRAX's annual financial statements (latest annual report filed July 6, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
VRAX valuation and financial ratios
Virax Biolabs earned a return on equity of −75.7% and a return on invested capital of −304.8% in fiscal 2026. It ended the year with $0.4 million of debt and $6.5 million in cash and short-term investments, a net cash position of $6.1 million.
See the VRAX income statement, the VRAX chart for price history, or the VRAX stock overview for the latest quote and news.
VRAX key metrics FAQ
What is Virax Biolabs's return on equity?
Virax Biolabs's return on equity (ROE) was −75.7% in fiscal 2026: net income of -$5.0 million on average shareholders' equity of $6.6 million.
What is Virax Biolabs's ROIC?
Virax Biolabs's return on invested capital was −304.8% in fiscal 2026, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Virax Biolabs have?
Virax Biolabs had total debt of $0.4 million at the end of fiscal 2026, a debt-to-equity ratio of 0.05 and more cash than debt.
What is Virax Biolabs's free cash flow yield?
Virax Biolabs generated -$4.9 million of free cash flow in fiscal 2026, a free cash flow yield of −223.1% on its market value at year-end ($2.2 million).
What is Virax Biolabs's current ratio?
Virax Biolabs's current ratio was 9.97 at the end of fiscal 2026: current assets were 9.97 times current liabilities.